Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

Inclusion Criteria: * Males and females of at least 18 years of age with stage IV or unresectable stage III non-ocular melanoma who may have received 0 to 2 prior regimens for metastatic disease with a biological therapy or immunotherapy (e.g., IL-2 or interferon-alfa). * Measurable disease according to Response Criteria for Solid Tumors (RECIST). * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1. * Estimated survival is greater or equal to 4 months. * Negative pregnancy test (women of childbearing potential only). * Pretreatment laboratory levels that meet specific criteria. * Signed informed consent, including permission to use protected health information. Exclusion Criteria: * Prior treatment with M200 or a5b1 inhibitors and murine or chimeric monoclonal antibodies. * Prior treatment with DTIC, temozolomide, or other chemotherapeutic regimens. * Known sensitivity to murine proteins or chimeric antibodies or other components of the product. * Use of any investigational drug within 4 weeks prior to screening or 5 half-lives of the prior investigational drug (whichever is longer). * Systemic biologic, immunotherapy, and/or radiation therapy within 4 weeks of the first dose of M200. * Documented central nervous system (CNS) tumor or CNS metastasis. * History of thromboembolic events and bleeding disorders within the past year. * Medical conditions that may be exacerbated by bleeding.